Ironwood Pharmaceuticals Company Profile (NASDAQ:IRWD)

About Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals logoIronwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IRWD
  • CUSIP: 46333X10
  • Web:
  • Market Cap: $2.23 billion
  • Outstanding Shares: 135,068,000
Average Prices:
  • 50 Day Moving Avg: $17.41
  • 200 Day Moving Avg: $17.17
  • 52 Week Range: $12.48 - $19.94
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -30.45
  • P/E Growth: -0.25
Sales & Book Value:
  • Annual Revenue: $270.81 million
  • Price / Sales: 7.44
  • Book Value: $0.03 per share
  • Price / Book: 497.33
  • EBIDTA: ($84,770,000.00)
  • Net Margins: -52.97%
  • Return on Equity: -333.83%
  • Return on Assets: -18.83%
  • Debt-to-Equity Ratio: 79.64%
  • Current Ratio: 4.27%
  • Quick Ratio: 4.27%
  • Average Volume: 1.19 million shs.
  • Beta: 1.45
  • Short Ratio: 13.49
Frequently Asked Questions for Ironwood Pharmaceuticals (NASDAQ:IRWD)

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its earnings results on Thursday, August, 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.05. The business earned $65.10 million during the quarter, compared to analyst estimates of $70 million. Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The business's revenue for the quarter was up 19.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.16) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

When will Ironwood Pharmaceuticals make its next earnings announcement?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Ironwood Pharmaceuticals.

Where is Ironwood Pharmaceuticals' stock going? Where will Ironwood Pharmaceuticals' stock price be in 2017?

9 equities research analysts have issued twelve-month target prices for Ironwood Pharmaceuticals' stock. Their predictions range from $13.00 to $23.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $18.50 in the next year. View Analyst Ratings for Ironwood Pharmaceuticals.

Who are some of Ironwood Pharmaceuticals' key competitors?

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:

  • Peter M. Hecht Ph.D., Chief Executive Officer, Director
  • Thomas Graney, Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
  • Mark G. Currie Ph.D., Senior Vice President, Chief Scientific Officer, President - Research and Development
  • Thomas A. McCourt, Senior Vice President - Marketing and Sales, Chief Commercial Officer
  • Halley E. Gilbert Esq., Senior Vice President, Chief Legal Officer, Secretary
  • Christopher I. Wright M.D. Ph.D., Senior Vice President - Global Development and Chief Development Officer
  • Terrance G. McGuire, Non-Executive Independent Chairman of the Board
  • Andrew Dreyfus, Independent Director
  • Marsha H. Fanucci, Independent Director
  • Julie H. McHugh, Independent Director

Who owns Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (12.59%), Vanguard Group Inc. (7.24%), Janus Henderson Group PLC (5.90%), State Street Corp (3.35%), EcoR1 Capital LLC (2.78%) and Pictet Asset Management Ltd. (1.28%). Company insiders that own Ironwood Pharmaceuticals stock include Edward P Owens, Gina Consylman, Halley E Gilbert, Lawrence S Olanoff, Mark G Currie, Peter M Hecht, Thomas A Mccourt and Thomas Graney. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Who sold Ironwood Pharmaceuticals stock? Who is selling Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Spark Investment Management LLC, Goldman Sachs Group Inc., Blue Jay Capital Management LLC, Gotham Asset Management LLC, Artal Group S.A., Alliancebernstein L.P. and Bank of Montreal Can. Company insiders that have sold Ironwood Pharmaceuticals stock in the last year include Gina Consylman, Halley E Gilbert, Lawrence S Olanoff, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Who bought Ironwood Pharmaceuticals stock? Who is buying Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, EcoR1 Capital LLC, Penn Capital Management Co. Inc., State Street Corp, State of Wisconsin Investment Board, New York State Common Retirement Fund, Pictet Asset Management Ltd. and Vanguard Group Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy Ironwood Pharmaceuticals stock?

Shares of Ironwood Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of Ironwood Pharmaceuticals stock can currently be purchased for approximately $14.92.

MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)
Community Ranking:  2.1 out of 5 ( )
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  306 (Vote Underperform)
Total Votes:  523
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ironwood Pharmaceuticals (NASDAQ:IRWD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $18.50 (23.99% upside)

Analysts' Ratings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Cowen and CompanySet Price TargetBuy$20.00HighView Rating Details
8/2/2017MizuhoReiterated RatingBuy$22.00 -> $23.00HighView Rating Details
7/22/2017Wells Fargo & CompanySet Price TargetBuy$19.00LowView Rating Details
7/21/2017Wood & CompanyDowngradeOverweight -> NeutralLowView Rating Details
7/21/2017J P Morgan Chase & CoReiterated RatingOverweight -> Neutral$20.00 -> $19.00HighView Rating Details
6/16/2017WedbushReiterated RatingNeutral$13.00LowView Rating Details
3/13/2017BTIG ResearchReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
2/22/2017Barclays PLCReiterated RatingEqual Weight -> Equal Weight$13.00 -> $16.00N/AView Rating Details
9/27/2016WallachBeth CapitalBoost Price TargetHold$15.00 -> $17.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingMarket Perform$10.00 -> $14.00N/AView Rating Details
4/28/2016JP Morgan CazenoveReiterated RatingOverweight$15.00N/AView Rating Details
4/26/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
3/21/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$14.00N/AView Rating Details
(Data available from 8/17/2015 forward)


Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Earnings by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Earnings History by Quarter for Ironwood Pharmaceuticals (NASDAQ IRWD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017N/AView Earnings Details
8/3/2017Q2 2017($0.23)($0.28)$70.00 million$65.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.19)($0.33)$69.39 million$52.16 millionViewListenView Earnings Details
2/21/2017Q416($0.24)($0.12)$77.34 million$87.50 millionViewListenView Earnings Details
11/3/2016Q316($0.23)($0.18)$60.01 million$66.00 millionViewN/AView Earnings Details
8/4/2016Q216($0.15)($0.16)$54.49 million$54.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.14)($0.08)$52.97 million$66.00 millionViewN/AView Earnings Details
2/18/2016Q415($0.17)($0.10)$44.78 million$53.30 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.25)$39.81 million$39.60 millionViewListenView Earnings Details
8/5/2015Q215($0.22)($0.34)$36.08 million$27.74 millionViewN/AView Earnings Details
5/5/2015Q115($0.23)($0.24)$32.30 million$28.90 millionViewN/AView Earnings Details
2/12/2015Q414($0.21)($0.27)$35.20 million$38.10 millionViewListenView Earnings Details
11/4/2014Q314($0.32)($0.30)$21.20 million$16.90 millionViewListenView Earnings Details
8/4/2014Q214($0.36)($0.38)$15.75 million$6.84 millionViewListenView Earnings Details
4/29/2014Q1($0.45)($0.38)$8.52 million$14.60 millionViewListenView Earnings Details
1/21/2014Q413($0.50)($0.43)$7.13 million$5.00 millionViewListenView Earnings Details
10/22/2013Q313($0.57)($0.51)$6.54 million$4.90 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.70)($0.57)$6.32 million$9.70 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.71)($0.87)$8.94 million$3.30 millionViewN/AView Earnings Details
1/15/2013Q4 2012($0.49)($0.41)$16.17 million$27.00 millionViewN/AView Earnings Details
10/16/2012$0.17$0.42ViewN/AView Earnings Details
7/17/2012($0.31)($0.38)ViewN/AView Earnings Details
5/1/2012($0.23)($0.34)ViewN/AView Earnings Details
2/28/2012($0.11)($0.07)ViewN/AView Earnings Details
11/7/2011($0.20)($0.21)ViewN/AView Earnings Details
8/11/2011($0.18)($0.19)ViewN/AView Earnings Details
5/12/2011($0.17)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)
2017 EPS Consensus Estimate: ($0.75)
2018 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.20)($0.22)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.21)($0.12)($0.17)
Q4 20172($0.19)($0.10)($0.15)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)


Dividend History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Insider Ownership Percentage: 7.63%
Institutional Ownership Percentage: 97.85%
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/22/2017Halley E GilbertInsiderSell35,000$19.75$691,250.00View SEC Filing  
5/15/2017Thomas A MccourtInsiderSell30,000$18.20$546,000.00View SEC Filing  
2/14/2017Halley E GilbertInsiderSell37,385$16.75$626,198.75View SEC Filing  
1/12/2017Peter M HechtCEOSell65,987$15.67$1,034,016.29View SEC Filing  
12/5/2016Lawrence S OlanoffDirectorSell3,200$15.68$50,176.00View SEC Filing  
9/6/2016Lawrence S OlanoffDirectorSell3,200$13.72$43,904.00View SEC Filing  
8/19/2016Gina ConsylmanInsiderSell207$13.54$2,802.78View SEC Filing  
6/3/2016Lawrence S OlanoffDirectorSell2,200$12.92$28,424.00View SEC Filing  
5/25/2016Halley E GilbertInsiderSell20,275$12.19$247,152.25View SEC Filing  
3/11/2016Peter M HechtCEOSell120,000$10.72$1,286,400.00View SEC Filing  
3/7/2016Lawrence S OlanoffDirectorSell2,200$11.11$24,442.00View SEC Filing  
2/24/2016Edward P OwensDirectorBuy10,000$8.32$83,200.00View SEC Filing  
2/24/2016Gina ConsylmanCAOSell420$8.50$3,570.00View SEC Filing  
2/24/2016Mark G CurrieInsiderSell152,154$8.53$1,297,873.62View SEC Filing  
2/24/2016Thomas GraneyCFOSell563$8.50$4,785.50View SEC Filing  
12/15/2015Peter M. HechtCEOSell73,418$11.07$812,737.26View SEC Filing  
12/7/2015Lawrence S OlanoffDirectorSell2,200$11.77$25,894.00View SEC Filing  
9/4/2015Lawrence S OlanoffDirectorSell3,725$10.97$40,863.25View SEC Filing  
3/17/2015Peter M HechtCEOSell200,000$15.62$3,124,000.00View SEC Filing  
3/12/2015Joseph C Cook JrDirectorSell5,883$15.54$91,421.82View SEC Filing  
3/10/2015Bryan E RobertsDirectorSell95,998$15.20$1,459,169.60View SEC Filing  
3/3/2015Peter M HechtCEOSell63,442$15.75$999,211.50View SEC Filing  
2/20/2015Joseph C Cook JrDirectorSell35,500$15.60$553,800.00View SEC Filing  
12/15/2014Bryan E RobertsDirectorSell19,792$15.20$300,838.40View SEC Filing  
6/12/2014Bryan E RobertsDirectorSell200,000$14.24$2,848,000.00View SEC Filing  
5/29/2014Michael J HigginsCOOSell50,000$14.56$728,000.00View SEC Filing  
5/22/2014Mark CurrieInsiderSell25,000$13.93$348,250.00View SEC Filing  
4/24/2014Mark CurrieInsiderSell25,000$11.67$291,750.00View SEC Filing  
1/23/2014Mark CurrieInsiderSell20,000$14.38$287,600.00View SEC Filing  
1/14/2014Bryan RobertsDirectorSell21,200$12.57$266,484.00View SEC Filing  
1/13/2014Bryan RobertsDirectorSell823,350$12.71$10,464,778.50View SEC Filing  
1/6/2014Bryan RobertsDirectorSell55,450$12.01$665,954.50View SEC Filing  
11/7/2013Terrance McguireDirectorSell2,083$9.11$18,976.13View SEC Filing  
6/17/2013Michael J HigginsCOOSell150,000$11.74$1,761,000.00View SEC Filing  
3/11/2013Thomas A MccourtInsiderSell40,000$17.00$680,000.00View SEC Filing  
11/5/2012Peter M HechtCEOBuy50,000$11.65$582,500.00View SEC Filing  
10/8/2012Fmr LlcInsiderSell19,305$13.02$251,351.10View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Latest Headlines for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateHeadline logoSee what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. - August 12 at 12:21 AM logoFY2021 EPS Estimates for Ironwood Pharmaceuticals, Inc. Reduced by Analyst (IRWD) - August 7 at 10:22 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Given a $20.00 Price Target by Cowen and Company Analysts - August 5 at 9:56 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - August 5 at 8:22 PM logoEdited Transcript of IRWD earnings conference call or presentation 3-Aug-17 8:30pm GMT - August 4 at 8:13 PM logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : August 4, 2017 - August 4 at 1:08 AM logoIronwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : August 4, 2017 - August 4 at 1:08 AM logoIronwood Pharmaceuticals Provides Second Quarter 2017 Investor Update - August 3 at 8:08 PM logoIronwood reports 2Q loss - August 3 at 8:08 PM logoMizuho Reiterates Buy Rating for Ironwood Pharmaceuticals, Inc. (IRWD) - August 2 at 8:22 PM logoIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Cut to Sell at BidaskClub - July 31 at 4:29 PM logoZacks: Brokerages Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) Will Announce Quarterly Sales of $68.48 Million - July 31 at 8:18 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Rating of "Hold" from Analysts - July 24 at 9:18 AM logoWells Fargo & Company Analysts Give Ironwood Pharmaceuticals, Inc. (IRWD) a $19.00 Price Target - July 23 at 10:41 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Earns Outperform Rating from Cowen and Company - July 23 at 3:04 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Given Buy Rating at Mizuho - July 23 at 3:04 PM logoIronwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease - July 22 at 10:15 PM logoJ P Morgan Chase & Co Reiterates "Neutral" Rating for Ironwood Pharmaceuticals, Inc. (IRWD) - July 22 at 2:53 PM logoIronwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : July 21, 2017 - July 22 at 2:16 AM logoIronwood's Pipeline Needs Work, Analyst Downgrades - July 22 at 2:16 AM logoIronwood (IRWD) Reports Positive Data on Reflux Candidate - July 22 at 2:16 AM logoWood & Company Downgrades Ironwood Pharmaceuticals, Inc. (IRWD) to Neutral - July 21 at 3:01 PM logoIronwood Pharmaceuticals (IRWD) IW-3718 Phase IIb Clinical Trial Results - Slideshow - July 21 at 12:02 AM logoIronwood Pharmaceuticals to Host Second Quarter 2017 Investor Update Call - July 21 at 12:02 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Upgraded at Zacks Investment Research - July 17 at 3:28 PM logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : July 13, 2017 - July 14 at 4:31 AM logo Brokerages Anticipate Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Will Announce Quarterly Sales of $68.47 Million - July 7 at 3:03 PM logoIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Upgraded at BidaskClub - July 6 at 11:28 PM logo-$0.23 EPS Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter - July 5 at 9:12 AM logoMizuho Increases Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Price Target to $22.00 - July 4 at 9:42 PM logoToday's Research Reports on Trending Tickers: Ironwood Pharmaceuticals and Under Armour - July 3 at 7:28 PM logoIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Cut to Hold at BidaskClub - June 30 at 10:23 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Receives Average Rating of "Hold" from Brokerages - June 27 at 8:20 AM logoInsider Selling: Ironwood Pharmaceuticals, Inc. (IRWD) Insider Sells 35,000 Shares of Stock - June 26 at 10:40 PM logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : June 26, 2017 - June 26 at 7:48 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Upgraded to "Buy" by BidaskClub - June 23 at 8:20 PM logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : June 16, 2017 - June 16 at 6:52 PM logoIronwood Pharmaceuticals' (IRWD) Neutral Rating Reaffirmed at Wedbush - June 16 at 1:46 PM logoIronwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 15, 2017 - June 16 at 6:21 AM logoWhy Is Ironwood (IRWD) Up 6.9% Since the Last Earnings Report? - June 12 at 6:35 PM logo Analysts Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) Will Post Quarterly Sales of $68.47 Million - June 11 at 10:28 AM logoIronwood Pharmaceuticals (IRWD) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 9 at 8:36 PM logoZacks: Brokerages Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) Will Post Earnings of -$0.23 Per Share - June 9 at 9:52 AM logoIronwood Pharmaceuticals to Present at the Goldman Sachs 38th Annual Global Healthcare Conference - June 8 at 6:58 PM logoIs Ironwood's Growth About to Slow? - June 5 at 10:11 AM logoValuEngine Upgrades Ironwood Pharmaceuticals, Inc. (IRWD) to Hold - June 4 at 10:38 AM logoIronwood Pharmaceuticals (IRWD) versus Juniper Pharmaceuticals (JNP) Head-To-Head Analysis - June 4 at 12:24 AM logoIronwood Pharmaceuticals to Present at the Jefferies Healthcare Conference - June 1 at 6:44 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Given Consensus Rating of "Hold" by Analysts - May 31 at 9:22 AM logoIronwood Pharmaceuticals, Inc. (IRWD) Short Interest Down 8.4% in May - May 27 at 7:18 AM



Ironwood Pharmaceuticals (IRWD) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by Staff